Newsroom
WHO includes our new pediatric treatment option for preschoolers with schistosomiasis in list of prequalified medicines
Following the positive scientific opinion by the European Medicines Agency in December 2023 of our new pediatric treatment option for preschool-aged children with schistosomiasis, we have another exciting milestone to announce: The World Health Organization (WHO) has now included our new treatment option in its List of Prequalified Medicines.
Context and significance
The WHO Prequalification Process (PQP) was established in 2001 in response to issues concerning the quality and availability of medicines. It is a service provided by the WHO to assess the quality, safety, and efficacy of medicinal products. This assessment has led to an improvement in the quality of life-saving medicines used by millions of people in low- and middle-income countries.
The WHO’s List of Prequalified Medicinal Products is also used by international procurement agencies and increasingly by countries to guide the bulk purchasing of medicines.
Together with the positive scientific opinion by EMA, the WHO prequalification of our new pediatric treatment option aims to support its adoption in endemic countries and facilitate equitable and sustainable access. Ultimately, it brings the new treatment one step closer to the young patients in need.